| Previous Close | 32.95 |
| Open | 33.09 |
| Bid | 32.87 x 500 |
| Ask | 32.89 x 600 |
| Day's Range | 32.65 - 33.08 |
| 52 Week Range | 27.60 - 56.44 |
| Volume | 988,894 |
| Avg. Volume | 7,597,803 |
| Market Cap | 33.31B |
| Beta | 0.52 |
| PE Ratio (TTM) | 420.38 |
| EPS (TTM) | 0.08 |
| Earnings Date | N/A |
| Dividend & Yield | 1.36 (4.17%) |
| Ex-Dividend Date | 2017-06-01 |
| 1y Target Est | 36.83 |
- MarketWatch•1 hour ago
UPDATED: Xenon and Teva say mid-stage nerve pain drug missed primary, secondary endpoints
Xenon Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. said premarket Tuesday that their mid-stage nerve pain drug missed its primary endpoint and secondary endpoints. Xenon shares plummeted ...
- 24/7 Wall St.•2 hours ago
Short Sellers Run for Cover From Major Pharma
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks shrank.
- GlobeNewswire•2 hours ago
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint
JERUSALEM and BURNABY, British Columbia, June 27, 2017-- Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announce top-line results in a Phase II study of topical TV-45070 in patients ...